Urinary bile acid excretion was studied by gas chromatography/mass spectrometry in 4 infants with intrahepatic cholestasis and pruritus, aged 4-20 months, before and after administration of P (10 mgl kglday). Serum levels of bilirubin and bile acids decreased but the activites of y-glutamyltransferase (S-GT) and alkaline phosphatases (S-ALP) mainly increased. Most infants increased their total bile acid excretion in urine by 4-fold. The percentage polyhydroxylated bile acids increased much more: before treatment tetra-0H-bile acids ranging from 0 to 7.6% (mean 2.4%) and after 3 to 100 weeks of treatment from 4.8 to 25.5 % (mean 17.2%) of total urinary bile acids (p<O.OOl). The predominant bile acids after treatment were cholic acid, 1,3,7,12 and 3,6, 7,12 tetra-0H-5 0-cholanoic acids and hyocholic acid. Excretion of chenodeoxycholic acid was mainly unchanged. The relative amounts of sulphated bile acids decreased in all cases after treatment, before being 52-68% (mean 60%) and after 13-56% (mean 33%). Although serum bilirubin levels decreased and polyhydroxylated bile acid excretion increased after P treatment, the increase of S-GT and S-ALP and the increased urinary excretion of cholic acid end total bile acids suggest more severe cholestasis. Our results indicate that further studies are necessary to show if P is beneficial in cholestatic disease in infancy. It might, on the contrary be a hazard in early infancy,and at presentaroutine administration to cholestatic infants is not recomnended.
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NUTRITI0NlTPN)-ASSOCIATED CHOLESTASIS. DC. Eelli. CC. &y. Depts of Pediatrics, Universities of Geneva and Montreal, 1211 Geneva 4, Switzerland. The quantity of perfused amino acids Ian), and their qualitative pattern, was thought to be a pathogenic factor of TPN-associated hepatotoxicity. Previous studies have shown an hypothetic protective effect of methyl donor aa. TO asaees whether and how SAME could normalize bile flow during infusion of as with dextrose, 4 groups of rats 157-1889 were studied after 5 days of TPN VamincV) or TravasolIT) with and without SAMe ), as well as a weight matched control group (C) receiving dextrose IV and chow orally. Concentration of methyl donor as was higher in V than in T. On TPN, the animals recsived 10.2 9 of glucoae and 3.4 9 of aa daily. After TPN, bile flow was measured and hepatocyte membranes were prepared and their composition determined. oolsize Eile acid metabolism was studied in 10 ERIC patients in a cholestasis free neriod. Primarv bile acid noolsizes were estimated simultanebusly using dekterated cholic ' acid (CAI and chenodeoxycholic acid (CDCA). The poolsiee of CA and CDCA ex ressed in pnol/k bodyveight were si nificantl contracted in B R~C patients: 8 .%r4.2 and 11.7f4.8, respecrively versus 24.1f11.7 and 22.9f7.8 in controls. Fractional turno;er rates (day-') for CA and CDCA were increased 0.70i0.29 and 0.5810.27 res ectively versus 0.29f0.12 and 0.2310.10 in controls. ~il; acis pool cdmposition in x in BRIC patients was CA 34i17 CDCA 38f9 deoxycholic acid (DCA 27ilE lithocholic acid (~d) lfl with' a glycineltaurine con]ugation0 Olf ratio of 6.7f4.9. The percenta e of sulphated bile acids never exceded 2% of the total amount 05 bile acids Corres onding values for 32 controls were:
CA 57*13 CDCA 29f9 bCA 14tB LCA <1 and a GlT ratio of 2 4fl 3
Faecal bile acid lods in polfk Ida was 11.2f9.0 in BRIC pitiet;t; corn ared to 2.8f1.4 in controfs. {he serum 7aOH-cholesterol and 260R-cholesterol in m l l L w e e increased si~nificantlv in ERIC patients 326f179 and 247f54 respectively "versus lSlf90 and 98f64 in controls. These ra;ulto sug eat that in BRIC patients increased spill-over of bile acids to t%e colon occurs which leads to increased faecal bile acid loss and a reduced bile acid no01 bile a d d synthesis; lt-is sugsestivi that-choiestatic igeritasin-i contracted pool might initiate an episode of cholestasis.
ChrOnlC bepatltls B virus IHBV) infectton in cblldren nay lead to bepatlc ClrrboslS and bepbtoBa, The antlviral effect of recolblMnt Interferon IrIFiJI In the treatment of cbronlc hepatitis In adults has been proven. For tbls reason, ue carried out a controlled study of therapy using r1FN-a In children ultb cbronlc bepatltls due to HBV.
A total of 24 chilCen (2-12 years) Mere randolly allocated In tuo groups: control (~1 2 1 and treatpent ~n=l?), ubo received 10 U l of rlFNv2A lhferonlllc bcdy surface. 1.n.. tbllCe weekly durlng 3 Mntbs, All of then ha6 a blstolcqical dlagnosls of C M and were BBsAg. HBeAg and HBV-MA posltlve for at least 6 MIIlhS before entry Into the study.
The treatment was uell tolerated a d all children colpleted tbe study. At tbe end of tbe treatment period. 3 w t of the 12 (33%) treated patients, becane HW-DNA negative, Another treated patlent lost HBV-DIIA at tbe 6tb wnth and a total of 4 patlents renalned Ilke that untll the l2tb mntb of follow-up. Hone of the controls lost HBV-OW), durlng tbe flrst SIX aotths of the study but 2 patlents belonging to tbls proup becane HBV-DWA negative at the 9th sonth and dnotber 2 at the 12tb lontb. A total of 4 treated patlents and 3 controls uere HBeRg negatlve at tbe 12th month of follou-up. A w k e d decrease In ALT levels, along tke four respoder children s s observed, In contrast no variations a~w non-responden uere dMected.
In sunnary. r1PN-a therapy In CM-HBV Infection In chlldren Iswell tolerated. In additlcn, an antlvlral effett was observed. Our prevlous results suggest that prolonged tberdpy (6 Ponths, thrlce ueexly) could be useful In the treatnent of cblldren ulth chronic 8BV !tfect ion
